MT 63-78

SKU: orb1308003

Description

MT 63-78 is a direct AMPK activator (EC50: 25 µM) with demonstrated antitumor activity. It inhibits prostate cancer cell growth in vitro by suppressing lipogenesis and mTORC1 signaling, leading to cell cycle arrest and apoptosis. Its effects have also been explored in relevant in vivo xenograft models.

Research Area

Cell Biology, Epigenetics & Chromatin, Signal Transduction

Key Properties

• CAS Number: 1179347-65-9
• MW: 326.35
• Purity: 98.95% (May vary between batches)
• Formula: C₂₁H₁₄N₂O₂
• SMILES: Oc1cccc(O)c1-c1ccc(cc1)-c1ccc2[nH]cc(C#N)c2c1
• Target: AMPK,Apoptosis,mTOR
• Solubility: DMSO:3.27 mg/mL (10.02 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (3.06 mM)

Bioactivity

• Target IC50:
  mTORC1:|AMPK:25 μM (EC50)
• In Vivo:
  MT 63-78 (30 mg/kg; intraperitoneal injection; daily; for 14 days; C57 BL/6 male mice) treatment results in a 33% inhibition of tumor growth.
• In Vitro:
  MT 63-78 (0-50 μM; 24 hours; LNCaP, PC3, C4-4, C4-2B, CL1 and 22RV1 cells) treatment induces a reduction of anti-apoptotic Mcl-1 and an accumulation of the pro-apoptotic BH3-only protein Puma. MT 63-78 (0-50 μM; 4 days; LNCaP and PC3 cells) treatment displays a dose-dependent decrease in cell number and activation of AMPK signaling. MT 63-78 (0-50 μM; 30 minutes; LNCaP and PC3 cells) treatment shows dose-dependent phosphorylation of AMPK targets Acetyl-CoA Carboxylase (ACC) on Ser79 and Raptor on Ser792, and increases Thr172 phosphorylation on the AMPK α subunit. MT 63-78 (25 μM; 24 hours; LNCaP and CRPC cells) treatment causes significant enrichment in the G2/M population.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

direct, dephosphorylation, AMP-activated protein kinase, BH3, Apoptosis, antitumor, AMPK, arrest, MT 63 78, MT 6378, MT 63-78, mTOR, mTORC1, inhibit, p53, lipogenesis, mitotic, Mcl-1, Mammalian target of Rapamycin, Inhibitor, Thr172, Raptor

Compound Identifiers

PubChem CID

59145386